Medical 21

Focus: Medical 21 is a biotechnology company focused on developing artificial grafts for cardiac bypass procedures, addressing a critical unmet need in cardiovascular surgery. The company operates as a specialized biotech player in the Minneapolis area with a narrow but clinically significant therapeutic focus.

Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Medical 21

AI assessmentNot Hiring

No open roles listed right now. Follow Medical 21 to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Sodium-GLucose coTransporter-2 inhibitors

Sodium-GLucose coTransporter-2 Inhibitors

N/A

PDO suture

Wrinkles

N/A

Clinical Trials (1)

Help build intelligence for Medical 21

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to contribute to a focused, specialized solution in high-stakes cardiovascular surgery with clear clinical utility
Early-stage biotech environment offers hands-on involvement in product development from clinical to commercialization stages
Minneapolis location provides access to strong medical device and biotech ecosystem with lower cost of living than coastal biotech hubs

Watch Out For

No active job openings reported suggests the company may be in dormant or stealth mode with limited near-term hiring
Complete lack of disclosed financial, clinical trial, and funding data raises questions about company maturity, capitalization, and ability to fund operations long-term

Generated by Claude from Medical 21's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.